ClinicalTrials.gg
TerminatedNCT03810898Updated May 6, 2023

iMagemHTT: FIH Evaluation of Novel Mutant Huntingtin PET Radioligands [¹¹C]CHDI-00485180-R and [¹¹C]CHDI-00485626

An Early Phase 1 interventional study of Radioligand [¹¹C]CHDI-00485180-R and Radioligand [¹¹C]CHDI-00485626 in Huntington Disease, sponsored by CHDI Foundation, Inc.. Terminated at 1 site in Belgium. Open to participants aged 20 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-05-06.

Sponsored by CHDI Foundation, Inc. · Early Phase 1, Interventional, and Other

How we know

Why this study was terminated
Study terminated per protocol design post interim analysis review after Phase 2a. No SAEs or safety issues were noted.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
20 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Huntington Disease by CHDI Foundation, Inc. — 2 open to participants now, 2 under way, none of them phase 3. Huntington Disease · CHDI Foundation, Inc..

Started
2021
the only one that year
Phase 1
4 of 11
1 open now
Registered
8th of 11
by date

Among the 11 studies in Huntington Disease by CHDI Foundation, Inc., this one is the only one that started in 2021, is one of 4 in phase 1, and was the 8th registered.

Huntington Disease

293 studies on the registry are indexed under Huntington Disease; 54 are open to participants now.

Browse Huntington Disease studies →

Open to participants now

2 of the 11 studies in Huntington Disease by CHDI Foundation, Inc. are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 43 Huntington Disease studies recruiting now, 19 (44%) set no upper age limit and 20 (47%) stop at 75 or younger; 5 take children under 18; 20 take healthy volunteers.

This study: 20 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Huntington Disease by CHDI Foundation, Inc., or all of them as a file.
02

Study summary

This is a FIH (first-in-human) adaptive PET (Positron Emission Tomography) imaging study to explore the binding and kinetic properties of two potential mutant huntingtin (mHTT) radioligands; [¹¹C]CHDI-00485180-R and [¹¹C]CHDI-00485626.

The binding characteristics of these radioligands will be evaluated first in young (\< 35 years of age) healthy control (HC) participants (Phase 1a) and subsequently in young HCs and Huntington's disease gene-expansion carriers (HDGECs) with Stage II HD (Phase 1b). Subsequent phases will continue to explore the radioligands' binding characteristics in HDGECs with Stage II HD (Phase 2a), Stage I HD (Phase 2b) and pre-manifest HDGECs (Phase 2c) and their age matched healthy controls. All phases are cross-sectional and will include comparisons between HCs and HDGECs. Test-retest (TRT) evaluations will be done during Phase 2a, with the option of including further test-retests in Phases 2b, and 2c after review of data by the iMagemHTT Executive Committee. TRT is only applicable to HDGEC participants.

There are four planned interim analyses at which either radioligand may be dropped if its characteristics are shown to be suboptimal. If successful, the study will establish [¹¹C]CHDI-00485180-R and/or [¹¹C]CHDI-00485626 as fit for further development as drug development tools to measure mHTT levels in HDGECs. This development is intended to demonstrate the value of PET imaging with these radioligands as a disease progression biomarker, predictive biomarker, pharmacodynamic biomarker, and eventually as an efficacy biomarker.

All HDGEC participants will be invited to provide an optional cerebrospinal fluid (CSF) sample that will be collected after the imaging visits are complete. These samples will be processed to evaluate CSF mHTT levels and other potential biomarkers and to explore potential relationships between soluble CSF mHTT levels and mHTT binding identified by [¹¹C]CHDI-00485180-R and/or [¹¹C]CHDI-00485626 PET imaging. Potential CSF biomarkers that might be co-expressed or accumulated in HD may also be examined.

Read the detailed description

The study investigators have developed two novel PET radioligands that will be evaluated for their suitability for use in clinical research settings to quantify mHTT in HDGECs. The PET radioligands do not have any pharmacological effect at the microdoses (total dose \<100ug) at which they will be administered; they will not be administered at pharmacological doses. This study has a modular design in two phases, and each phase will enroll a small independent cohort. The execution of each subsequent phase is dependent on results from the previous phase.

Phase 1 is the initial evaluation of the PET radioligands. A suitable PET radioligand is expected to produce quantifiably higher binding in HD participants' brains compared to young HC participants' brains (since they do not express mHTT). Phase 1 is divided in two sub phases: Phase 1a will evaluate the basic safety and kinetic properties as well as brain uptake in three (3) young HCs; Phase 1b will test the difference in binding in six (6) HDGECs with Stage II HD compared to six (6) young HCs (three (3) young HCs will be imaged in addition to the three (3) young HCs from 1a. The rationale behind using young HCs in Phase 1 is to screen out HC participants who may have undiagnosed amyloid-β (Aβ) plaques, a potential off-target binding site for [¹¹C]CHDI-00485180-R. The rationale behind imaging HDGECs with Stage II HD in Phase 1 is based on the hypothesis that the density of mHTT aggregates increases with disease severity, and the ability to detect a difference in binding between HCs and HDGECs is expected to be higher in Stage II HD (more severe stages of HD will not be included in this study). An option to image three (3) pre-manifest HDGECs from Phase 2c (see below) will be included in case the results indicate that brain atrophy (i.e., loss of aggregate due to atrophy) affects the binding and evaluation of the PET radioligands in HDGECs with Stage II HD. For each of the two PET radioligands a Go/ No-Go evaluation will take place (for overview see Figure 1); if satisfactory results are not obtained for a particular radioligand, then that radioligand will not progress to evaluation in further phases. Promising results for either radioligand will lead to that particular radioligand continuing to Phase 2 evaluation.

Phase 2 will evaluate the sensitivity of the PET radioligand(s) to discriminate between different stages and severity of HD. In addition, a TRT in Phase 2 will evaluate the variability of repeated imaging for the PET radioligand. Phase 2 has a sequential design in sub phases that will assess the sensitivity of the radioligand in descending severity of HD: 2a in six (6) HDGECs with Stage II HD and six (6) age-matched controls; 2b in six (6) HDGECs with Stage I HD and six (6) age-matched controls; 2c in six (6) premanifest HDGECs and six (6) age-matched controls. The rationale for imaging groups of descending HD severity is based on the hypothesis that the density of mHTT aggregates increases with disease severity, and the ability to detect a difference in binding between HCs and HDGECs is expected to be lowest in the premanifest stage. This design will enable a stepwise assessment of the sensitivity of the PET radioligands. After each sub-phase a Go/No-Go evaluation will take place; if satisfactory results are not obtained for a particular radioligand then that radioligand will not be evaluated in further sub-phases. Promising results for either radioligand will lead to that particular radioligand continuing to the next sub-phase.

This study design allows each radioligand to be reviewed and analyzed after evaluation in each cohort. The progression through each level of analysis will indicate whether either or both radioligands will measure mHTT aggregate levels with sufficient sensitivity to become potential disease progression and efficacy biomarker(s) in HDGECs.

03

Conditions studied

  • Huntington Disease

Browse trials for

Keywords

  • Huntington Disease
  • Huntington's Disease
  • HD
  • HDGEC
  • Gene Expansion Carrier
  • PET
  • Tracer
  • Positron Emission Tomography
  • radioligand
  • imaging
  • mHTT
  • huntingtin
  • iMagemHTT
04

Who can participate

Ages eligible
20 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Pre-manifest HDGECs, HDGECs with Stage I HD, HDGECs with Stage II HD and HC participants:

  • Female and male adults, age 20-65 years old, inclusive.
  • (BMI) between 19 and 35 inclusive.
  • Capacity to give full in writing, and have read and signed the informed consent form (ICF).
  • Are capable of complying with study procedures, including fasting and blood sampling
  • Able and willing to travel to imaging PET center in Leuven, Belgium.
  • Willing to comply with the use of adequate measures.

Pre-manifest HDGECs:

  • Do not have clinical diagnostic motor features of HD, defined as Unified Huntington's Disease Rating Scale (UHDRS) Diagnostic Confidence Score \< 4; and
  • Have CAG expansion ≥ 40; and
  • Have a CAP score > 70 (as calculated with CAP formula: AGE * (CAG - 30) / 6.49).

HDGECs with Stage I HD:

  • Have clinical diagnostic motor features of HD, defined as UHDRS Diagnostic Confidence Score = 4; and
  • Have CAG expansion ≥ 40; and
  • Have Stage I HD, defined as UHDRS Total Functional Capacity (TFC) scores between 11 and 13 inclusive.

HDGECs with Stage II HD:

  • Have clinical diagnostic motor features of HD, defined as UHDRS Diagnostic Confidence Score = 4; and
  • Have CAG expansion ≥ 40; and Have Stage II HD, defined as UHDRS Total Functional Capacity (TFC) scores between 7 and 10 inclusive.

HC participants:

  • Have no known family history of HD; or
  • Have known family history of HD but have been tested for the huntingtin gene glutamine codon (CAG) expansion and are not at genetic risk for HD (CAG \< 36).
  • Matched by age +/- 5 years.
  • (Phase 1 only) under 35 years of age.

Exclusion criteria

Exclusion Criteria:

Pre-manifest HDGECs, HDGECs with Stage I HD, HDGECs with Stage II HD, and HC participants:

  • Currently participating in or less than 30 days after completing participation in other therapeutic or imaging studies.
  • Previous participation in PET imaging study that, cumulatively with the current study, will exceed annual regulatory limits for radiation exposure.
  • Any disease, condition, or concomitant medication that significantly compromises the function of the body systems and that in the opinion of the Investigator, might interfere with the conduct of the study or its interpretation.
  • Pregnant and breastfeeding females.
  • Concomitant medication (ConMed) use of antiplatelet or anticoagulant therapy (inclusive of acetylsalicylic acid). (See full ConMed list attached.)
  • Needle phobia.

HDGEC participants:

  • If using any antidepressant, psychoactive, psychotropic or other medications or nutraceuticals used to treat HD, the use of inappropriate (e.g., non-therapeutically high) or unstable dose within 30 days prior to participation.

HC participants:.

  • Family history of HD (unless genetic test confirming negative results).

For participants in optional CSF sample collection:

  • Frequent headache, significant lower spinal deformity or major surgery; or
  • Bleeding disorder.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Early Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Phase 1 (a & b)

    Radioligand \[¹¹C\]CHDI-00485180-R and/or Radioligand \[¹¹C\]CHDI-00485626/ 6 Stage II HDGECs and 6 young (\< 35) HCs/ Imaging- MRI and PET/ Both radioligands administered- 1x each/ Optional CSF collection for HDGECs

    Radiation: Radioligand [¹¹C]CHDI-00485180-R · Radiation: Radioligand [¹¹C]CHDI-00485626

  • Experimental
    Phase 2a

    Per Radioligand- Radioligand \[¹¹C\]CHDI-00485180-R or Radioligand \[¹¹C\]CHDI-00485626/ 6 Stage II HDGECs and 6 age matched HCs/ Imaging- MRI and PET/ 1 Radioligand administered 2x (test re-test)- HDGECs/ Optional CSF collection for HDGECs 1 Radioligand administered 1x- HCs/

    Radiation: Radioligand [¹¹C]CHDI-00485180-R · Radiation: Radioligand [¹¹C]CHDI-00485626

  • Experimental
    Phase 2b

    Per Radioligand- Radioligand \[¹¹C\]CHDI-00485180-R or Radioligand \[¹¹C\]CHDI-00485626/ 6 Stage I HDGECs and 6 age matched HCs/ Imaging- MRI and PET/ 1 Radioligand 1 or 2x administered (test re-test optional)- HDGECs/ Optional CSF collection for HDGECs 1 Radioligand administered 1x -HCs/

    Radiation: Radioligand [¹¹C]CHDI-00485180-R · Radiation: Radioligand [¹¹C]CHDI-00485626

  • Experimental
    Phase 2c

    Per Radioligand- Radioligand \[¹¹C\]CHDI-00485180-R or Radioligand \[¹¹C\]CHDI-00485626/ 6 Pre-manifest HDGECs and 6 age matched HCs/ Imaging- MRI and PET/ 1 Radioligand administered 1 or 2x (test re-test optional)- HDGECs/ Optional CSF collection for HDGECs 1 Radioligand administered 1x- HCs/

    Radiation: Radioligand [¹¹C]CHDI-00485180-R · Radiation: Radioligand [¹¹C]CHDI-00485626

Interventions

  • RadiationRadioligand [¹¹C]CHDI-00485180-R

    Intravenous injection of radioligand in the arm with PET imaging of the brain.

  • RadiationRadioligand [¹¹C]CHDI-00485626

    Intravenous injection of radioligand in the arm with PET imaging of the brain.

06

What researchers measure

Primary outcomes

  1. The VT (volume of distribution total) of 2 discrete PET markers will be measured with PET imaging.

    VT (volume of distribution total) is derived from the data collected during each PET scan. VT is the amount of the PET marker in a volume of tissue (i.e., a concentration).

    Time frame: Single point measure- 90 minutes scan

07

Study locations

1 site
  • Universitaire Ziekenhuizen Leuven/ UZ Leuven/ UZL
    Leuven, 3000, Belgium
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2021 to primary completion in Feb 2023, 24 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2018
First posted
Jan 22, 2019
StartActual
Feb 9, 2021
Primary completionActual
Feb 15, 2023
CompletionActual
Feb 15, 2023
Last update
May 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03810898
Lead sponsor
CHDI Foundation, Inc.
Responsible party
Sponsor
First posted
Jan 22, 2019
Start date
Feb 9, 2021
Primary completion
Feb 15, 2023
Completion
Feb 15, 2023
Last update
May 6, 2023

Study contacts

Wim Vandenberghe, MD, PhD
principal investigator · Universitaire Ziekenhuizen Leuven/ UZ Leuven/ UZL
Mette Skinbjerg, PhD
study director · CHDI Management/ CHDI Foundation

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion